查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1598713

1 型糖尿病藥物市場：按形式、最終用戶分類 - 2025-2030 年全球預測

Type 1 Diabetes Drug Market by Form (Insulin Therapy, Oral Medication), End User (Drugstore, Hospital) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年1型糖尿病藥物市值為175.7億美元，預計到2024年將達到191.4億美元，複合年成長率為9.06%，到2030年將達到322.4億美元。

1 型糖尿病藥物市場的特點是全球對胰島素和相關藥物的需求，這對於治療第 1 型糖尿病至關重要，而第 1 型糖尿病是一種胰腺分泌很少或不分泌胰島素的慢性疾病。如果沒有適當的治療，第1型糖尿病可導致心血管疾病和神經病變等嚴重併發症，因此迫切需要有效的藥物來維持血糖值。 1 型糖尿病藥物的使用範圍正在從個別患者的使用範圍擴大到專注於糖尿病治療的醫院、診所和研究機構。大多數新診斷病例是兒童和青壯年，因此最終使用病例主要是兒童和青壯年。

主要市場統計
基準年[2023] 175.7億美元
預測年份 [2024] 191.4億美元
預測年份 [2030] 322.4億美元
複合年成長率（%） 9.06%

推動市場成長的主要因素是全球糖尿病盛行率的增加、醫療技術的進步以及糖尿病管理意識的提高。下一代胰島素製劑和口服胰島素製劑等生物技術創新為市場參與者擴大其產品組合提供了重要機會。此外，人們越來越重視個人化醫療方法和數位健康解決方案的開發，例如智慧胰島素筆和連續血糖監測儀，以提高治療效果和患者依從性。然而，仍存在可能阻礙成長的挑戰，例如嚴格的法律規範、高昂的開發成本以及藥物的潛在副作用。此外，由於獲得醫療保健和負擔能力的差異，新興市場的市場開拓仍然有限。

創新和研究的一個重要領域在於閉合迴路胰島素輸送系統的開發以及人工智慧技術和糖尿病管理工具的結合，以更準確地預測胰島素需求。在這些領域的投資有可能進一步簡化糖尿病護理，改善患者的生活品質，並最終降低醫療成本。如果公司能夠克服監管障礙並利用技術進步來滿足 1 型糖尿病患者不斷變化的需求，那麼該市場仍然高度活躍，並且具有相當大的成長潛力。

市場動態：揭示快速發展的 1 型糖尿病藥物市場的關鍵市場洞察

供需的動態交互作用正在改變第 1 型糖尿病藥物市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 全球第 1 型糖尿病發生率增加
    • 可支配收入增加導致醫療支出增加
    • 提高患者對第 1 型糖尿病治療的認知
  • 市場限制因素
    • 藥品專利到期
  • 市場機會
    • 新型抗糖尿病藥物的推出增多
    • 1型糖尿病藥物研發快速成長
  • 市場挑戰
    • 藥品核准的嚴格規定

波特五力：駕馭第 1 型糖尿病藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解第 1 型糖尿病藥物市場的外部影響

外部宏觀環境因素在塑造第 1 型糖尿病治療藥物市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解第1型糖尿病治療藥物市場的競爭狀況

對第 1 型糖尿病治療藥物市場的詳細市場佔有率分析可以對供應商的業績進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 1 型糖尿病藥物市場定位矩陣供應商績效評估

FPNV 定位矩陣是評估第 1 型糖尿病藥物市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃 1 型糖尿病藥物市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對 1 型糖尿病治療藥物市場進行策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球 1 型糖尿病的發生率正在增加
      • 可支配所得增加導致醫療費用增加
      • 提高患者對第 1 型糖尿病治療的認知
    • 抑制因素
      • 藥品專利到期
    • 機會
      • 糖尿病治療新藥介紹
      • 1型糖尿病藥物研發活動迅速增加
    • 任務
      • 對認證核可藥的嚴格規定
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 1 型糖尿病藥物市場：依形式

  • 胰島素治療
    • 長效胰島素
    • 預混合料模擬
    • 速效胰島素
  • 口腔醫學
    • 雙胍
      • Metformin
      • Metformin緩釋性
    • 鈉葡萄糖共同輸送體2 (SGLT2) 抑制劑
      • 卡格列淨
      • Dapagliflozin
      • Empagliflozin
      • 艾格列淨

第 7 章 1 型糖尿病藥物市場：依最終使用者分類

  • 藥局
  • 醫院

第8章北美和南美1型糖尿病藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區第一型糖尿病藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲第1型糖尿病治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • B. Braun Melsungen AG
  • Biocon Limited
  • DAIICHI SANKYO COMPANY, LIMITED
  • Eli Lilly and Company
  • GSK plc
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Samsung Bioepis Co., Ltd.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • XOMA Corporation
Product Code: MRR-43676CF429EB

The Type 1 Diabetes Drug Market was valued at USD 17.57 billion in 2023, expected to reach USD 19.14 billion in 2024, and is projected to grow at a CAGR of 9.06%, to USD 32.24 billion by 2030.

The Type 1 Diabetes Drug market is characterized by the global demand for insulin and related medications essential for managing Type 1 Diabetes, a chronic condition where the pancreas produces little or no insulin. As Type 1 Diabetes can lead to serious complications like cardiovascular disease and nerve damage if untreated properly, there is a pressing necessity for effective medications to maintain blood sugar levels. Application of Type 1 Diabetes drugs extends beyond personal patient use to include hospitals, clinics, and research institutions focused on diabetes treatment. The end-use scope predominantly consists of children and young adults, as this demographic represents the majority of new diagnosis cases.

KEY MARKET STATISTICS
Base Year [2023] USD 17.57 billion
Estimated Year [2024] USD 19.14 billion
Forecast Year [2030] USD 32.24 billion
CAGR (%) 9.06%

Market growth is primarily fueled by increasing prevalence rates of diabetes globally, advancements in medical technology, and heightened awareness regarding diabetes management. Biotechnological innovations, such as next-generation insulin products and oral insulin, offer substantial opportunities for market players to expand their portfolios. Additionally, there is a growing emphasis on developing personalized medicine approaches and digital health solutions, such as smart insulin pens and continuous glucose monitors, to enhance treatment efficacy and patient compliance. However, challenges persist, including stringent regulatory frameworks, high development costs, and the potential side effects of drugs, which can impede growth. Moreover, disparities in healthcare access and affordability continue to limit market reach in developing regions.

The best areas for innovation and research lie in the development of closed-loop insulin delivery systems and combining AI technology with diabetes management tools to predict insulin needs more accurately. Investments in these areas could further streamline diabetes care, enhance patient quality of life, and ultimately reduce healthcare costs. The market remains highly dynamic, with considerable potential for growth, provided companies can navigate regulatory hurdles and leverage technological advancements to meet the evolving needs of patients with Type 1 Diabetes.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Type 1 Diabetes Drug Market

The Type 1 Diabetes Drug Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing incidences of type 1 diabetes globally
    • Increasing healthcare expenditure with rising disposable income
    • Rising patient awareness on type 1 diabetes treatment
  • Market Restraints
    • Patent expiration of drugs
  • Market Opportunities
    • Emerging introduction of novel drugs to treat diabetes
    • Surge in research and development activities for type 1 anti-diabetic drugs
  • Market Challenges
    • Strict regulations for the approval drugs

Porter's Five Forces: A Strategic Tool for Navigating the Type 1 Diabetes Drug Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Type 1 Diabetes Drug Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Type 1 Diabetes Drug Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Type 1 Diabetes Drug Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Type 1 Diabetes Drug Market

A detailed market share analysis in the Type 1 Diabetes Drug Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Type 1 Diabetes Drug Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Type 1 Diabetes Drug Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Type 1 Diabetes Drug Market

A strategic analysis of the Type 1 Diabetes Drug Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Type 1 Diabetes Drug Market, highlighting leading vendors and their innovative profiles. These include Astellas Pharma Inc., AstraZeneca PLC, B. Braun Melsungen AG, Biocon Limited, DAIICHI SANKYO COMPANY, LIMITED, Eli Lilly and Company, GSK plc, Johnson & Johnson Services, Inc., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Samsung Bioepis Co., Ltd., Sanofi S.A., Teva Pharmaceutical Industries Ltd., and XOMA Corporation.

Market Segmentation & Coverage

This research report categorizes the Type 1 Diabetes Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Form, market is studied across Insulin Therapy and Oral Medication. The Insulin Therapy is further studied across Long-Acting Insulin, Premix Analogs, and Rapid Acting Insulin. The Oral Medication is further studied across Biguanides and Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors. The Biguanides is further studied across Metformine and Metformine Extended-Release. The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors is further studied across Canaglifozine, Dapagliflozine, Empagliflozine, and Ertugliflozine.
  • Based on End User, market is studied across Drugstore and Hospital.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing incidences of type 1 diabetes globally
      • 5.1.1.2. Increasing healthcare expenditure with rising disposable income
      • 5.1.1.3. Rising patient awareness on type 1 diabetes treatment
    • 5.1.2. Restraints
      • 5.1.2.1. Patent expiration of drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging introduction of novel drugs to treat diabetes
      • 5.1.3.2. Surge in research and development activities for type 1 anti-diabetic drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Strict regulations for the approval drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Type 1 Diabetes Drug Market, by Form

  • 6.1. Introduction
  • 6.2. Insulin Therapy
    • 6.2.1. Long-Acting Insulin
    • 6.2.2. Premix Analogs
    • 6.2.3. Rapid Acting Insulin
  • 6.3. Oral Medication
    • 6.3.1. Biguanides
      • 6.3.1.1. Metformine
      • 6.3.1.2. Metformine Extended-Release
    • 6.3.2. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
      • 6.3.2.1. Canaglifozine
      • 6.3.2.2. Dapagliflozine
      • 6.3.2.3. Empagliflozine
      • 6.3.2.4. Ertugliflozine

7. Type 1 Diabetes Drug Market, by End User

  • 7.1. Introduction
  • 7.2. Drugstore
  • 7.3. Hospital

8. Americas Type 1 Diabetes Drug Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Type 1 Diabetes Drug Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Type 1 Diabetes Drug Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Astellas Pharma Inc.
  • 2. AstraZeneca PLC
  • 3. B. Braun Melsungen AG
  • 4. Biocon Limited
  • 5. DAIICHI SANKYO COMPANY, LIMITED
  • 6. Eli Lilly and Company
  • 7. GSK plc
  • 8. Johnson & Johnson Services, Inc.
  • 9. Novartis AG
  • 10. Novo Nordisk A/S
  • 11. Pfizer Inc.
  • 12. Samsung Bioepis Co., Ltd.
  • 13. Sanofi S.A.
  • 14. Teva Pharmaceutical Industries Ltd.
  • 15. XOMA Corporation

LIST OF FIGURES

  • FIGURE 1. TYPE 1 DIABETES DRUG MARKET RESEARCH PROCESS
  • FIGURE 2. TYPE 1 DIABETES DRUG MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. TYPE 1 DIABETES DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. TYPE 1 DIABETES DRUG MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. TYPE 1 DIABETES DRUG MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. TYPE 1 DIABETES DRUG MARKET DYNAMICS
  • TABLE 7. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY LONG-ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PREMIX ANALOGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY RAPID ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY METFORMINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY METFORMINE EXTENDED-RELEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CANAGLIFOZINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DAPAGLIFLOZINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY EMPAGLIFLOZINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ERTUGLIFLOZINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUGSTORE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 78. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
  • TABLE 81. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
  • TABLE 83. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 84. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 86. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
  • TABLE 87. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
  • TABLE 89. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 90. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 91. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 92. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
  • TABLE 93. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
  • TABLE 95. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 96. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 97. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 98. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
  • TABLE 99. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
  • TABLE 101. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 102. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 103. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 104. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
  • TABLE 105. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
  • TABLE 107. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 108. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 110. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
  • TABLE 111. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 114. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 116. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
  • TABLE 117. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
  • TABLE 119. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 120. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 121. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 128. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
  • TABLE 129. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
  • TABLE 131. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 132. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 134. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
  • TABLE 135. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
  • TABLE 137. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 138. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 139. VIETNAM TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 140. VIETNAM TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
  • TABLE 141. VIETNAM TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. VIETNAM TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
  • TABLE 143. VIETNAM TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 144. VIETNAM TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 152. DENMARK TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 153. DENMARK TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
  • TABLE 154. DENMARK TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 155. DENMARK TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
  • TABLE 156. DENMARK TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 157. DENMARK TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. EGYPT TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 159. EGYPT TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
  • TABLE 160. EGYPT TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. EGYPT TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
  • TABLE 162. EGYPT TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 163. EGYPT TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 164. FINLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 165. FINLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
  • TABLE 166. FINLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. FINLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
  • TABLE 168. FINLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 169. FINLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 170. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 171. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
  • TABLE 172. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 173. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
  • TABLE 174. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 175. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 176. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 177. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
  • TABLE 178. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 179. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
  • TABLE 180. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 181. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 182. ISRAEL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 183. ISRAEL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
  • TABLE 184. ISRAEL TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 185. ISRAEL TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
  • TABLE 186. ISRAEL TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 187. ISRAEL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 188. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 189. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
  • TABLE 190. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 191. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
  • TABLE 192. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 193. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 194. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 195. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
  • TABLE 196. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 197. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
  • TABLE 198. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 200. NIGERIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 201. NIGERIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
  • TABLE 202. NIGERIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 203. NIGERIA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
  • TABLE 204. NIGERIA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 205. NIGERIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 206. NORWAY TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 207. NORWAY TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
  • TABLE 208. NORWAY TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 209. NORWAY TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
  • TABLE 210. NORWAY TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 211. NORWAY TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 212. POLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 213. POLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
  • TABLE 214. POLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 215. POLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
  • TABLE 216. POLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 217. POLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 218. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 219. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
  • TABLE 220. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 221. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
  • TABLE 222. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 223. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 224. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 225. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
  • TABLE 226. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 227. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
  • TABLE 228. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 229. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 230. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 231. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
  • TABLE 232. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 233. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
  • TABLE 234. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 236. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 237. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
  • TABLE 238. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 242. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 243. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
  • TABLE 244. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 245. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
  • TABLE 246. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 247. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 248. SWEDEN TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 249. SWEDEN TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
  • TABLE 250. SWEDEN TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 251. SWEDEN TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
  • TABLE 252. SWEDEN TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 253. SWEDEN TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 254. SWITZERLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 255. SWITZERLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
  • TABLE 256. SWITZERLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 257. SWITZERLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
  • TABLE 258. SWITZERLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 260. TURKEY TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 261. TURKEY TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
  • TABLE 262. TURKEY TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 263. TURKEY TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
  • TABLE 264. TURKEY TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 265. TURKEY TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 266. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 267. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
  • TABLE 268. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 269. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
  • TABLE 270. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 278. TYPE 1 DIABETES DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 279. TYPE 1 DIABETES DRUG MARKET, FPNV POSITIONING MATRIX, 2023